SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Virgin Galactic Holdings, Inc. is an aerospace and space travel company, which engages in the provision of consumer space experience using reusable spaceflight systems. The firm is also involved in designing, developing, and manufacturing, ground and flight testing, spaceflight operation, and post-flight maintenance of spaceflight systems. The company was founded on May 5, 2017 and is headquartered in Tustin, CA.

Virgin Galactic Holdings Inc - Ordinary Shares - Class A

Virgin Galactic Holdings Inc

Virgin Galactic is experiencing extreme volatility and heavy retail-driven volume as investors bet on the stock as a proxy for upcoming space sector catalysts and the anticipated SpaceX IPO. The community is sharply divided between bulls anticipating a massive short squeeze and bears warning of potential dilution and a repeat of past pump-and-dump patterns.

Keel Infrastructure Corp. engages in building artificial intelligence focused data centers and energy assets. It focuses on infrastructure and energy required to support high-performance computing and artificial intelligence workloads. The company was founded on April 1, 2026 and is headquartered in New York, NY.

Keel Infrastructure Corp.

Keel Infrastructure Corp

Keel Infrastructure is seeing significant investor attention as market participants anticipate upcoming data center lease announcements, with many viewing the company's 2.2 GW power pipeline as an undervalued asset. The community is actively discussing management's shift toward high-performance computing infrastructure and the potential for a major rerating as the company moves closer to securing its first hyperscaler contract.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors react to a massive new stake disclosed by Leopold Aschenbrenner's fund, which has fueled speculation of a potential partnership with Anthropic and triggered a sharp surge in price. The community is heavily focused on the stock's role as a leader in AI infrastructure, with many debating the impact of increased institutional backing, analyst price target upgrades, and the ongoing short squeeze dynamics.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is currently trending as investors debate the massive capital expenditures directed toward AI infrastructure against the company's recent launch of new subscription services. While some community members remain skeptical of the spending levels, others are actively loading the boat, viewing the stock as an undervalued opportunity to capture long-term growth in the AI sector.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is seeing a surge in investor interest and speculative momentum, fueled by a combination of resurfaced high-level endorsements and significant government-backed investments in quantum computing and enterprise AI infrastructure. The community is actively debating the stock's potential for a transformative 'Intel-style' rally, with many viewing it as a safer, undervalued play compared to flashier, high-valuation AI tech names.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Cedar Park, TX.

Firefly Aerospace Inc.

Firefly Aerospace is seeing intense volatility and active retail debate following a public offering that triggered a significant price disconnect from recent highs. Investors are weighing the impact of dilution against strong sector tailwinds, including new NASA contract wins and the ongoing anticipation of the broader space economy's growth surrounding the SpaceX IPO.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently facing intense volatility and downward pressure as market participants debate the sustainability of recent rallies against a backdrop of geopolitical uncertainty and shifting institutional sentiment. Community discussion is sharply divided, with bulls pointing to long-term cyclical patterns while bears emphasize the recent selling of holdings by major corporate entities and a rotation of capital into high-growth AI stocks.

Strategy, Inc. is a Bitcoin Treasury company. The firm has adopted Bitcoin as a primary treasury reserve asset. It uses proceeds from equity and debt financing, as well as cash flows from operations, to strategically accumulate Bitcoin and advocate for its role as digital capital. Its treasury strategy is designed to provide investors varying degrees of economic exposure to Bitcoin by offering a range of securities, including equity and fixed-income instruments. It provides industry AI-powered enterprise analytics software. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is facing intense scrutiny as a rare sale of Bitcoin holdings and growing concerns over its liquidity and dividend obligations spark a heated debate among investors. The community remains deeply polarized, with critics warning of a potential death spiral while bulls argue that the volatility is merely a tactical opportunity to accumulate positions.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

Hyperliquid Strategies Inc. (PURR) is seeing a surge in investor attention due to its structural potential for a gamma squeeze, fueled by its low float and integration with the fast-growing Hyperliquid crypto ecosystem. The community is actively debating the stock's role as a unique treasury play while closely monitoring upcoming index inclusions and its performance relative to the HYPE token.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as investors closely track the progress of ivonescimab, with community sentiment fueled by anticipation of key clinical trial readouts and its potential to disrupt the lung cancer market. While some participants express caution regarding trial data originating from global or Chinese cohorts, others remain highly bullish, pointing to institutional backing and the company's strategic positioning against established big pharma benchmarks.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up

BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of +17.71% and +80.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Biogen Gears Up to Report Q2 Earnings: Here's What to Expect

Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.

What Makes Sage Therapeutics (SAGE) a New Buy Stock

Sage Therapeutics (SAGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms

Equity

Analysts have also noted that the relatively low breakup fee may leave room for a competing offer, possibly from Biogen.

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics

Under the terms of the deal, Supernus is looking to acquire Sage for a total consideration of $12 per share in cash.


Why Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report?

Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail

The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.


Sage Therapeutics Stock Eyes Best Day In 5 Years On Biogen’s Unsolicited Bid: Retail Piles In

The two companies have collaborated since 2020 on the depression drug Zurzuvae, approved in 2023 by the FDA for treating postpartum depression.


Macy's, Abercrombie and Moderna fall premarket; Sage soars

Investing.com -- US stock futures fell Monday, as investors fretted that the hot jobs report will prompt the Federal Reserve to hold back on rate cuts this year.

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.76	--	--	N/A
Q2 '25	-$0.94	-$0.79	16.12%	BEAT
Q1 '25	-$0.99	-$1.01	-1.53%	MISSED
Q4 '24	-$1.48	-$1.56	-5.17%	MISSED
Q3 '24	-$1.54	-$1.53	0.80%	BEAT

SAGESage Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '25

Historical Earnings

Latest SAGE News